Your browser doesn't support javascript.
loading
Biliverdin Reductase B Is a Plasma Biomarker for Intraplaque Hemorrhage and a Predictor of Ischemic Stroke in Patients with Symptomatic Carotid Atherosclerosis.
Chemaly, Melody; Marlevi, David; Iglesias, Maria-Jesus; Lengquist, Mariette; Kronqvist, Malin; Bos, Daniel; van Dam-Nolen, Dianne H K; van der Kolk, Anja; Hendrikse, Jeroen; Kassem, Mohamed; Matic, Ljubica; Odeberg, Jacob; de Vries, Margreet R; Kooi, M Eline; Hedin, Ulf.
Afiliação
  • Chemaly M; Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Marlevi D; Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Iglesias MJ; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
  • Lengquist M; Science for Life Laboratory, Department of Protein Science, School of Engineering Sciences in Chemistry/Biotechnology and Health, KTH Royal Institute of Technology, 11428 Stockholm, Sweden.
  • Kronqvist M; Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Bos D; Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden.
  • van Dam-Nolen DHK; Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
  • van der Kolk A; Department of Epidemiology, Erasmus MC, University Medical Center, 3000 CA Rotterdam, The Netherlands.
  • Hendrikse J; Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
  • Kassem M; Department of Medical Imaging, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
  • Matic L; Department of Radiology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
  • Odeberg J; Department of Radiology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
  • de Vries MR; Department of Radiology and Nuclear Medicine, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, 6229 ER Maastricht, The Netherlands.
  • Kooi ME; Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Hedin U; Science for Life Laboratory, Department of Protein Science, School of Engineering Sciences in Chemistry/Biotechnology and Health, KTH Royal Institute of Technology, 11428 Stockholm, Sweden.
Biomolecules ; 13(6)2023 05 24.
Article em En | MEDLINE | ID: mdl-37371462
ABSTRACT

BACKGROUND:

Intraplaque hemorrhage (IPH) is a hallmark of atherosclerotic plaque instability. Biliverdin reductase B (BLVRB) is enriched in plasma and plaques from patients with symptomatic carotid atherosclerosis and functionally associated with IPH.

OBJECTIVE:

We explored the biomarker potential of plasma BLVRB through (1) its correlation with IPH in carotid plaques assessed by magnetic resonance imaging (MRI), and with recurrent ischemic stroke, and (2) its use for monitoring pharmacotherapy targeting IPH in a preclinical setting.

METHODS:

Plasma BLVRB levels were measured in patients with symptomatic carotid atherosclerosis from the PARISK study (n = 177, 5 year follow-up) with and without IPH as indicated by MRI. Plasma BLVRB levels were also measured in a mouse vein graft model of IPH at baseline and following antiangiogenic therapy targeting vascular endothelial growth factor receptor 2 (VEGFR-2).

RESULTS:

Plasma BLVRB levels were significantly higher in patients with IPH (737.32 ± 693.21 vs. 520.94 ± 499.43 mean fluorescent intensity (MFI), p = 0.033), but had no association with baseline clinical and biological parameters. Plasma BLVRB levels were also significantly higher in patients who developed recurrent ischemic stroke (1099.34 ± 928.49 vs. 582.07 ± 545.34 MFI, HR = 1.600, CI [1.092-2.344]; p = 0.016). Plasma BLVRB levels were significantly reduced following prevention of IPH by anti-VEGFR-2 therapy in mouse vein grafts (1189 ± 258.73 vs. 1752 ± 366.84 MFI; p = 0.004).

CONCLUSIONS:

Plasma BLVRB was associated with IPH and increased risk of recurrent ischemic stroke in patients with symptomatic low- to moderate-grade carotid stenosis, indicating the capacity to monitor the efficacy of IPH-preventive pharmacotherapy in an animal model. Together, these results suggest the utility of plasma BLVRB as a biomarker for atherosclerotic plaque instability.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças das Artérias Carótidas / Placa Aterosclerótica / AVC Isquêmico Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Biomolecules Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças das Artérias Carótidas / Placa Aterosclerótica / AVC Isquêmico Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Biomolecules Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia
...